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Transport interactions of different organic cations during their excre-
tion by the intact rat kidney. Organic cations, in addition to being filtrated,
are secreted or reabsorbed in the proximal renal tubule whereby they have
to pass the contraluminal and the luminal cell membrane. Interactions
with the transport of other organic cations can occur at either cell side,
leading to inhibition or stimulation of net secretion or net reabsorption. A
qualitative evaluation of such processes is possible by using the in vivo
bolus injection of an organic cation as test substance. Measuring its
urinaly excretion profile in relation to that of inulin, under control
conditions and after application of interfering organic cations, in combi-
nation with simultaneous registration of its tissue concentration, allows the
demonstration of interaction and also the tentative identification of the
cell side at which interference has taken place. As test substance the
fluorescent organic cation 4-(4-dimethylaminostyryl)-N-methylpyridinium
(4-Di-1-ASP; denotes permanent positively-charged organic cations
was used, having a protein binding of 47% under the given experimental
conditions. As interfering organic cations amiloride, benzylamiloride,
choline, cimetidine, and 2-methyl-4-(heptafluorobutoxy-N-methylpyri-
dinium were injected. It was found that: (1) 4-Di-1-ASP is filtered and
net reabsorbed under control conditions (fractional excretion 0.54 0.1).
All net secreted interfering substances, except bidirectional transported
choline, injected simultaneously with 4-Di-1-ASP, showed an interfer-
ence with renal excretion of net reabsorbed 4-Di-1-ASP, by (2) instan-
taneously increasing its reabsorption, resulting in a 28 to 33% decrease in
urinary excretion, and (3) augmenting its tissue concentration by 19 to
58%. (4) A prolonged effect of the interfering substrates could be
observed after a third injection of 4-Di-1-ASP (without inhibitor)
showing an increased tissue concentration of 4-Di-1-ASP of 36 to 46%.
The complex interfering pattern of the applied organic cations can be
explained by a trans-stimulation of 4-Di-1-ASP net reabsorption at the
luminal cell side, leading to an increased intracellular content of 4-Di-1-
ASP.
Previous experiments on the kidney in situ have defined two
parameter kinetics for the transport of N1-methylnicotinamide
(NMeN; denotes permanent positively-charged organic cat-
ions) through the contraluminal cell membrane of the proximal
tubule, and for N-methyl-4-phenylpyridinium (MPP) and cho-
line through the luminal cell membrane [1, 2]. Furthermore, flux
coupling phenomena as cis-inhibition and trans-stimulation by
other organic cations and H ions have been observed. It was also
shown that a wide variety of organic cations, among them many
drugs, interact with the three transport systems [2]. With regard to
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drug excretion and nephrotoxicity, it is important to know whether
a given organic cation is net secreted or net reabsorbed, and what
types of interference with other organic cations do occur.
Since the same questions are also pertinent for the overall renal
handling of organic anions, the bolus injection/urinary excretion
method was established [3]. After intravenous application of a test
substance, its excretion profile relative to that of inulin, under
control conditions and after coinjection of interfering substances
was measured. Simultaneous registration of the concentration of
the test substance in the superficial tissue of the kidney, for the
proximal tubular cells, which make up 70% of kidney surface [4],
allows the identification at which cell side interference has taken
place. As test substances we used fluorescent dyes, sulfofluores-
cein (SF) in a previous [3] and 4-(4-dimethylaminostyryl)-N-
methylpyridinum (4-Di-1-ASP) in this study, which are sub-
strates for several organic anion and organic cation transport
systems. For being a suitable test substance, the fluorescent dye
had to yield a good tissue fluorescence signal, and to be sufficiently
excreted within the urine. To fulfill these requirements, the
respective dye has to be transported at a high rate, which is
commonly achieved by a reasonable affinity for the transport
system.
For organic cation transport, we were able to identify as test
substance the flourescent organic cation 4-(4-dimethylamino-
styryl)-N-methylpyridinum (4-Di-1-ASP). Examining its excre-
tion by the rat kidney, we found that 4-Di-1-ASP is net
reabsorbed, and that several interfering organic cations, which are
net secreted, are acutely enhancing its reabsorption, thereby
leading to an increase in tissue concentration of 4-Di-1-ASP.
Methods
Chemicals and drugs
4-(4-Dimethylaminostyryl)-N-methylpyridinium (4-Di-1-ASP)
and 2-(6-amino-3-imino-3H-xanthen-9-yl) benzoic acid methyl
ester (rhodamine 123) were obtained from Molecular Probes
(Eugene, OR, USA). Amiloride and choline were purchased
from Merck (Darmstadt, Germany), benzylamiloride from Re-
search Biochemicals International (Natick, MA, USA), and ci-
metidine from Sigma (Deisenhofen, Germany). 2-Methyl-4-(hep-
tafluorobutoxy)-N-methylpyridinium was a gift from Dr. Lang
(Hoechst AG, Frankfurt, Germany). [14C]Inulin was obtained
from Du Pont (Dreieich, Germany).
Animal preparation
Experiments were performed on male Wistar rats (Winkel-
mann, Kirchborchen, Germany) 200 to 230 g of body weight,
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which were fed on Altromin standard diet and tap water. The
animals were anesthetized by thiopental-sodium injection (Trap-
anal®; Byk Gulden, Konstanz, Germany), 120 to 150 mg/kg body
weight, i.p. and placed on a heated operating table with a
thermostat control set at 37°C. For injection of the test and
interfering substances via a polyethylene catheter, the left jugular
vein was cannulated. A small abdominal incision with placing
another polyethylene catheter into the urinary bladder was made
for collection of urine samples. Access to the left kidney was
achieved by incision of the flank. After separation from the
surrounding fascia the kidney was immobilized in a small plastic
cup on cotton wool. Renal artery, vein and the ureter were left
intact and in situ.
Measurement of tissue fluorescence
The device for continuous monitoring tissue content of the
fluorescent cations was developed in our laboratory [5]. Briefly, it
consists of an illuminating unit, a detector, and recording equip-
ment. For generating light with a wavelength close to the excita-
tion values of the fluorescent organic cations 4-(4-dimethylami-
nostyryl)-N-methylpyridinium (4-Di-1-ASP) and Rhodamine
123 (Rho 123), a halogen lamp (GBD 6433; Philipps, Kassel,
Germany) together with several optical filters were used: a heat
absorption filter (Spindler, Gottingen, Germany), a filter with
variable angle (DT blue, Balzers, Liechtenstein), a dichroic filter
magenta (DT magenta, Balzers, Liechtenstein), and a condenser
(Spindler) for focusing to the light guide (type DB-3000, Deutsche
Nichimen, Düsseldorf, Germany). The resulting light was guided
through fiber optics to the surface of the kidney. To detect the
emission from the superficial tissue of the kidney, a silicon
photodiode (S 1133; Hamamatsu, Herrsching, Germany) was
connected with two further filters: a band pass filter (DT green,
Balzers, Liechtenstein) and a BG18 filter (Deutsche Nichimen).
The detection signal was amplified, and plotted on a chart
recorder (Abimed, Langenfeld, Germany). During the experi-
ments, the fluorescence equipment was positioned close to the
surface of the kidney, with the light guide fixed in a suitable angle
to the detection unit, allowing a continuous registration of
changes in superficial kidney tissue fluorescence.
Determination of the apparent K, values for the used substances
To test whether test and interfering substances were substrates
for the contraluminal transport system for NMeN [1], the
luminal Ht'organic cation exchanger or the luminal transport
system for choline [2], stop-flow peritubular capillary perfusion
experiments and luminal perfusion experiments were performed.
The methods of measuring contraluminal and luminal influx of
labeled substances into proximal tubular cells and the mode of
evaluating transport parameters have been described previously
[1, 2], using [3H1N1-methylnicotinamide (NMeN) for studying
the contraluminal organic cation transport, [3H]N-methyl-4-phe-
nylpyridinium (MPP) for studying the luminal H/organic cat-
ion exchange and [3H]choline for studying the luminal transport
system of choline, with [14C]inulin as an extracellular space
marker.
Experiments
After preparing the animals, an osmotic diuresis was induced
with a starting dose of 1 ml of 20% mannitol solution infused into
the jugular vein over five minutes, followed by a continuous
infusion of 10% mannitol solution with 5% bovine serum albumin
(BSA) at an infusion rate of 3 ml/hr. After reaching a constant
urine flow rate of 0.06 to 0.08 mi/mm, 0.125 ml of the test solution
containing 4.9 m of 4-Di-1-ASP and 0.08 m of [14C]inulin
were injected into the jugular vein as control. Urine samples were
collected at five minute intervals until the excretion of the
fluorescent dye had almost ceased. After this time interval of
about 40 minutes, a second injection was made, consisting of 0.125
ml interacting substance together with test substance (4-Di-1 -
ASP 4.9 mrvi) and ['4C]inulin (0.08 mM). Interacting substances
were used at the following concentrations: amiloride (24.5 mM),
benzylamiloride (24.5 mM), cimetidine (49 mM) choline (74 and
147 mM) and 2-methyl-4-(heptafluorobututoxy)-N-methylpyri-
dinium (98 mM). After another 40 to 50 minutes of collecting
time, 0.125 ml of test substance (4-Di-1-ASP 4.9 mM) and
['4C]inulin (0.08 mM) were injected again. During the whole
experiment a tissue concentration of 4Di1ASP® was continu-
ously registrated.
Measurement of 4-Di-1-ASP and ['4C]inulin content in urine
samples and calculation of normalized excretion rates
The fluorescence measurements of 4-Di-1-ASP and Rho 123
in urine were carried out on a spectrofluorophotometer (Shi-
madzu RF-510; Gamma Analysentechnik, Bremerhaven, Ger-
many) with excitation/emission wavelengths being 470 nm/605 nm
and 495 nm/523 nm, respectively. A total of 0.1 ml of the original
urine sample was diluted with 0.1 ml of 0.1 N NaOH solution and
2.9 ml of bidistilled water. Fluorescence intensities were cali-
brated with 4-Di-1-ASP-containing standards. Urinary [14C]inu-
lin concentration was measured in a Betamatic scintillation
counter (Kontron, Düsseldorf, Germany). Ten microliters of the
original urine sample was diluted in 100 jsl of bidistilled water and
5 ml of scintillation coctail (Picofluor 15; Packard, Frankfurt,
Germany). The largest urinary excretion of [14C]inulin over 25
minutes (5 urine samples) after the first injection was used as
control (100%), as was used the excretion of 4-Di-1-ASP over 25
minutes after appearing in the urine. For the second/third bolus
injection, the measured and calculated urinary excretion rates had
to be corrected for the amount of ['4Clinulin and 4-Di-1-ASP
that was still being excreted because of the first/second injection of
[4C]inulin and 4-Di-1-ASP9. This was done by graphically ex-
trapolating the urinary excretion rates of the first/second injection
and subtracting them from the second/third injection excretion
rates. After correction of the excretion rates of the second/third
injection, they could be related to those of the first injection. In
each five minute urine sample, the amounts of [14C]inulin and
4-Di-1-ASP were determined, the values of the five samples
containing the largest amount of substance after i.v. injection
summed up (interfering substances in most of the cases caused a
delay in 4-Di-1-ASP excretion) and related to the injected
amount.
Evaluation of the tissue concentration of 4-Di-1-ASP
Three parameters of tissue concentration were determined: (1)
the maximal fluorescence intensity in tissue, expressed as the
maximal height of the tissue concentration (hm,), given in
arbitrary units, that is, millimeters of excursion of the recorded
trace; (2) the half time of decay of fluorescence in renal tissue
(t112) given in minutes; (3) the area under the curve of the
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fluorescence signal to quantify the tissue content of 4-Di-1-ASP.
The area was integrated over five minutes, beginning from the
rise in tissue concentration after injection, given in arbitrary units
(mm x mm).
Measurement of plasma protein binding
Plasma protein binding of 4-Di-1-ASP and Rho 123 was
determined by the method described by De Lange et a! 61. Rats
were Set under osmotic diuresis similar to the experiments. Three
to five minutes after the injection of either 0.125 ml 4.9 mM
4-Di-1-ASP or Rho 123 (0.61 jsmol) into the jugular vein, the
blood of the animals was drawn from the right ventricle, and the
plasma was then separated by centrifugation. To yield the un-
bound fraction, the plasma was centrifuged with ultracentrifuga-
tion units (Centricon-Tm30; Amicon, Witten, Germany). The
concentrations of the fluorescent organic cations in plasma and
ultrafiltrate were determined as described above. Plasma protein
binding (P) was calculated according to the equation: P = (Cgotai —
ce)Ictotai with c,1 being the total dye concentration in plasma,
and being the dye concentration in the ultrafiltrate.
Calculation of the fractional excretion
The calculation of the ratio of 4-Di-1-ASP excretion to inulin
excretion was made by using the 25-minute excretion rates of
4-Di-1-ASP and inulin under control conditions and after
injection of interfering substances. For evaluating the fractional
excretion, that is, the ratio excreted amount/filtered amount of
4-Di-1-ASP and Rho 123, the fluorescent organic cation/inulin
excretion ratio had to be multiplied by cfO,//cfr of the respective
substance.
Microscopical investigation of renal tissue slices
Renal tissue slices were investigated by application of fluores-
cence microscopy to obtain further information about the intra-
cellular distribution pattern of 4-Di-1-ASP and Rho 123 in
proximal tubular cells. Therefore, rats were prepared and set
under osmotic diuresis as in the other experiments (see above)
and 0.125 ml of each fluorescent dye injected at different concen-
trations (Rho 123 at 0.1, 0,25, 1, 2.5 and 5 mM; 4-Di-1-ASP at 1
and 5 mM). At the anticipated peak tissue fluorescence (30
seconds after injection) the left kidney was removed and shock
frozen in liquid propane, cooled by liquid nitrogen. The kidneys
were then stored in liquid nitrogen until 2 to 4 sm sections were
cut with a cryotome at — 25°C and thaw-mounted onto glass slides.
Dried slices were enclosed by DePex (Serva 18243, Heidelberg,
Germany) or Mowiol (Hoechst AG, Frankfurt, Germany) and a
cover glass, then investigated with a Zeiss Axiophot fluorescence
microscope with a water immersion objective at a magnification of
25, filter combination BP 450—490/FT 510/LP 520.
Statistical analysis
Paired t-tests were performed for estimating the effects of
interfering substances on 4-Di-1-ASP transport. For urinary and
fractional excretion of 4-Di-1-ASP the values obtained under
coinjection with inhibitor (injection 2) were calculated against the
two control values of injection 1 and 3, which did not differ
significantly. For tissue concentration of 4-Di-1-ASP the values
of injections 2 and 3 were calculated against control value
(injection 1). A P level <0,05 was considered to be statistically
significant.
Results
Apparent K, values of test and inhibitory substrates
The K, data show that for 4-Di-1-ASP and Rho 123, which are
net reabsorhed, both luminal K, values are by a factor of 3 to 20
lower than the respective contraluminal K, values. On the other
hand, substrates which are net secreted, that is, cimetidine,
amiloride, benzylamiloride and 2-methyl-4-(heptafluorobutoxy)-
N-methylpyridinium have contraluminal K1 values which are in
the same range (by a factor of 2) or lower than the luminal K,
values. Choline, which is at low concentrations net reabsorbed
and at high concentrations net secreted has a contraluminal K,
value which is 8 times higher than that for the luminal choline'
transporter but 15 times lower than that for the luminal H/
organic cation exchanger. Thus, the K, values indicate in which
direction net transport proceeds.
Excretion rates of the fluorescent test substrates within the urine
and protein binding
Five five-minute urine samples after injection containing the
most substance were used to determine the excretion rate of the
fluorescent dyes and [14C]inulin. Taking all controls, an average
excretion rate of 58.0 5.4% (47.8 to 66.7%; N = 24) of injected
inulin over 25 minutes was found. The respective values for the
fluorescent dyes were 16.9 4.2% (11.1 to 25.7%; N = 24) for
4-Di-1-ASP and 3.1 0.4% for Rho 123 (2.7 to 3.3%; N = 3).
Plasma protein binding of 4-Di-1-ASP and Rho 123 were found
to be 47% and 72%, respectively. The resulting factors for
calculation of the fractional excretion (FE) were 1.89 for 4-Di-1-
ASP and 3.57 for Rho 123. The FE values were calculated as
0.55 0.1 (0.42 to 0.79; N 24) for 4-Di-1-ASP and 0.16 0.02
(0.14 to 0.18; N = 3) for Rho 123. Thus 4-Di-1-ASP® as well as
Rho 123 were net reabsorbed by the rat kidney.
Results
Apparent K values of test and inhibitory substrates
The K, data show that for 4-Di-1-ASP and Rho 123, which
were net resorbed, both luminal K, values were by a factor of 3 to
20 lower than the respective contraluminal K, values. On the other
hand, substrates which, were net secreted, that is, cimetidine,
amiloride, benzylamiloride and 2-methyl-4-(heptafluorobutoxy)-
N-methylpyridinium had contraluminal K, values which were in
the same range (by a factor of 2) or lower than the luminal K,
values. Cho!ine, which, was at low concentrations net reab-
sorbed and at high concentrations net secreted had a contralumi-
nal K, value which was 8 times higher than that for the luminal
choline transporter but 15 times lower than that for the lumina!
H/organic cation exchanger. Thus, the K, values indicated which
direction net transport proceeds.
Excretion rates of the fluorescent test substrates within the utine
and protein binding
Five five-minute urine samples after injection containing the
most substance were used to determine the excretion rate of the
fluorescent dyes and ['4Cjinulin (Table 1). Taking all controls, an
average excretion rate of 58.0 5.4% (47.8 to 66.7%; N = 24) of
injected inulin over 25 minutes was found. The respective values
for the fluorescent dyes were 16.9 4.2% (11.1 to 25.7%; N 24)
for 4-Di-1-ASP and 3.1 0.4% for Rho 123 (2.7 to 3.3%;
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Table 1. Fluorescent test substances and inhibitory substrates: chemical structures, PKa values and apparent K, values against luminal (1) and
contraluminal (cI) organic cation transport systems
Chemical structure pK k, i MPPF
H
Cimetidine NCN H3C..N 6.8
II
CH3-NH-C-NH-CH2-CH2-S-CH
NH
Amiloride
CRN CO—NH—C—NH2
N'NH2
2-Methyt-4-
(heptafluorobutoxy)-N-
methylpyridinium CH3—-0--CH2—(CF2)2—CF3
CH3
0.83±0.11 0.55*0.13 0.04±0.03
13.5 21.2*7.15 O.18(Km)
The luminal (1) apparent K1 values (mean SE) were evaluated according to David et al [2 with Nmethyl4phenylpyridiniurn (MPPu) and
choline as test substrates. The contraluminal (cl) apparent K, values were evaluated with N -methylnicotinamide (NMeN) as test substrate
according to Ullrich et al [1]. The pK values for 4-Di-1-ASP and Rho 123 were determined spectrofluorophotometrically at room temperature and
constant ionic strength conditions by using 0.1 N NaCl solution as solvent; other pK values were derived from the literature.
N = 3). Plasma protein binding of 4-Di-1-ASP and Rho 123
were found to be 47% and 72%, respectively. The resulting factors
for calculation of the fractional excretion (FE) were 1.89 for
4-Di-1-ASP and 3.57 for Rho 123. The FE values were calcu-
lated as 0.55 0.1 (0.42 to 0.79; N = 24) for 4-Di-1-ASP and
0.16 0.02 (0.14 to 0.18; N = 3) for Rho 123. Thus 4-Di-1-ASP
as well as Rho 123 were net reabsorbed by the rat kidney.
Change in urinary excretion and tissue concentration of 4-Di-1-
ASP due to simultaneous injection of interfering substances
Because of lower plasma protein binding and higher urinary
excretion rate, 4-Di-1-ASP was chosen as the test substance for
the inhibition experiments. Figures 1 and 2 depict two represen-
tative experiments, demonstrating the changes in urinary excre-
tion and tissue concentration of 4-Di-1-ASP under the influence
of the inhibitory substances amiloride and cimetidine. When the
interfering substance was injected simultaneously with 4-Di-1-
ASP into the jugular vein, an effect on both urinary excretion
and tissue content of the test substance could be seen. Amiloride,
injected at an amount of 3.1 mol simultaneously with 4-Di-1-
ASP (0.61 mol) caused a delay and reduction of 4-Di-1-ASP
excretion within the urine by 19% compared to the control, while
inulin excretion was not altered significantly. The tissue curve of
4-Di-1-ASP, showing an increase of hm and a prolongation of
t112, resulted in an increase in tissue concentration (area under the
curve) of 50%. When 4-Di-1-ASP was injected a third time
(without amiloride), an augmented urinary excretion of 4-Di-1-
ASP (131% of control), together with an increase in tissue
concentration of 4-Di-1-ASP (134% of control) could be ob-
served. The same effects were produced by cimetidine, as shown in
Figure 2. Under simultaneous injection of 6.1 j.mol of cimetidine
together with 4-Di-1-ASP the decrease of 29% and the delay in
urinary excretion of 4-Di-1-ASP, compared to the control, were
much more pronounced. The increase in tissue concentration of
4-Di-1-ASP' caused by cimetidine was due to a marked prolon-
gation of t112, leading to a 75% increase of tissue content of
4-Di-1-ASP. The prolonged effect of cimetidine on urinary
excretion and tissue content of 4-Di-1-ASP seen after the next
injection of 4-Di-1-ASP without inhibitor, was comparable to
that observed with amiloride, showing an increase of 28% in
urinary excretion of 4-Di-1-ASP and an increase in tissue
concentration of 4-Di-1-ASP of 70% compared to the control.
Table 2 and 3 summarize the effects of the five organic cations
investigated under the consideration of interference with the renal
Substance I choIine k, c NMeN
4-(4-Dimethylaminostyryl)- CH3N— CH= CH —3.— N(CH3)2 3.6
N-methylpyridinium
(4-Di-1 -ASPe)
H2N _.. 0 NH
Rhodamine 123
(Rho 123) 0CH3
mmol/lite
0.10±0.02 0.014±0.003 0.28±0.12
12.3 0.02 * 0.003 0.058 0.011 0.34 0.12
0.07±0.01 2.05±0.05 0.16±0.04
8.7 0.13
0.02 0.002 0.025 0.008 0.05 * 0.02Benzylamiloride
CLNCO—NH—— NHCH2-
H2N N NH2
Cholinee OH—CH2—CH2—N+-(CH3)3 1.40*0.44
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Fig. 1. Renal excretion and tissue fluorescence of
the cationic fluorescent dye 4-(4-
dimethylaminosty,yl)-N-methylpyridinium (4-Di-1-
ASP) and the effect of amiloride. Arrows: bolus
injection of 0.125 ml 4.9 mM (0.61 jsmol) 4-Di-
1-ASP, or coinjection with 24.5 m (total
volume 0.125 ml = 3.1 imoI) amiloride into
the jugular vein. Each injection also contained
0.01 mol of ['4C}inulin. A. Time curve of
continuously monitored tissue fluorescence
intensity of 4-Di-1-ASP (in arbitrary units)
under control conditions (4-Di-1-ASP,
[14Ciinulin) and after injection of inhibitor (4-
Di-1-ASP, [14C]inulin plus amiloride). B.
Ratio of excreted amount of 4-Di-1-ASP and
[14C]inulin in each 5-mm urine sample in
percent of the injected amount. C. Diuresis for
each 5-mm urine sample.
Fig. 2. Effect of cimetidine on renal excretion
and tissue fluorescence of the cationic fluorescent
dye 4-(4-dimethylaminosty,yl)-N-methylpyridinium(4-Di-1-ASP). Cimetidine was coinjected at a
concentration of 49 m (total volume 0.125 ml
= 6.1 j.Lmol). For further details, see legend to
Fig. 1.
transport of 4-Di-1-ASP. Four of them [3 as buffers: cimetidine,
amiloride, benzylamiloride; 1 with a permanent positive change:
2-methyl-4-(heptafiuorobutoxy)-N-methylpyridinium)] showed
an identical interference pattern with 4-Di-1-ASP excretion.
The effects were as follows: decrease in urinary excretion of
4-Di-1-ASP after simultaneous injection (cimetidine —33
13%, P < 0.0001; amiloride —30 12%, P < 0.001; benzylamilo-
ride —29 16%, P < 0.001; and 2-methyl-4-(heptafiuorobutoxy)-
N-methylpyridinium —28 23%, P < 0.001). Simultaneous
increase in tissue concentration (area under the curve) after
coinjection with 4-Di-1-ASP (cimetidine 58 13%, P < 0.0001;
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amiloride 58 40%, P < 0.01; benzylamiloride 47 19%, P <
0.001; and 2-methyl-4-(heptafiuorobutoxy)-N-methylpyridinium
19 33%, P < 0.05). Choline exhibited no significant interfer-
ence with urinary excretion or tissue concentration of 4-Di-1-
ASP' (—16 11% (NS, Table 2) and 5 27% (NS, Table 3),
respectively). When 4-Di-1-ASP was injected without using an
interfering substance, after the second injection no significant
change in urinary excretion of 4-Di-1-ASP could be noted.
However, for the third injection of 4-Di-1-ASP (without inhib-
itor) an increase in urinary excretion compared to the first
injection could be observed; this value is important as time control
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Table 2. Urinary excretion of 4-Di-1-ASP and [14Cjinulin
Inulin excretion over 25 4-Di-1-ASP excretion
mm over 25 mm
% of injected amount Ratio % of injected amount Ratio
Injection 1 2 3 2/1 3/1 1 2 3 2/1 3/1
Fraction excretion
(4-(Di-1-ASP° X 1.89/
inulin) Ratio
I 2 3 2/1 3/1
Control 54.87 52.36 55.02 0.95 1.0 13.34 12.64 16.22 0.98 1.26 0.46 0.46 0.57 1.04 1.27
4.14 12.6 14.2 0.17 0.19 3.14 2.10 2.90 0.20 0.29 0.12 0.04 0.07 0.07 0.22
Choline° 49.81 40.63 41.31 0.81 0.86 14.19 11.98 12.9 0.84 0.95 0.52 0.54 0.59 1.04 1.11
10.2 9.27 6.59 0.03 0.25 5.15 5.12 4.77 0.11 0.27 0.1 0.17 0.15 0.19
Cimetidine° 61.58 55.13 64.14 0.89 1.04 18.99 12.53° 21.52 0.67 1.13 0.59 043d 0.63 0.74 1.09
3.66 12.0 6.01 0.16 0.08 1.72 2.45 4.35 0.13 0.19 0.08 0.01 0.07 0.09 0.19
Amiloridea 62.31 54.89 60.43 0.87 0.97 19.92 14.61° 20.06 0.7 1.03 0.61 0.50° 0.64 0.83 1.06
4.98 12.4 13.5 0.16 0.18 5.17 5.02 4.78 0.12 0.02 0.15 0.12 0.11 0.04 0.09
Benzy1amiloride 61.05 65.30 58.77 1.05 0.96 19.07 1364d 21.35 0.71 1.12 0.60 0.38' 0.68 0.72 1.16
4.02 8.43 10.2 0.09 0.13 4.68 4.64 6.56 0.16 0.21 0.17 0.13 0.14 0.11 0.11
2-Methyl-4- 58.83 52.04 59.73 0.87 1.01 15.78 1115b 18.88 0.72 1.21 0.51 041d 0.60 0.81 1.20
(hepafluoro- 7.19 16.7 10.9 0.23 0.23 1.79 3.29 3.60 0.23 0.27 0.08 0.04 0.02 0.09 0.18
butoxy)-N-
methyl-
pyridinium
Values are means SD of four experiments; for concentrations of injected substances see text.
a Inhibitor injected at injection 2
"P < 0.05, P < 0.01, P < 0.001, aP < 0.0001 different from control (injections 1 and 3)
Table 3. Tissue fluorescence of 4-Di-1-ASP
Decay of fluorescence Area under the curve
Maximal height tl1max] [t,,2] 5 mm]
mm Ratio mm Ratio (mm X mm) Ratio
Injection 1 2 3 2/1 3/1 1 2 3 2/1 3/1 1 2 3 2/1 3/1
Control 40.75 39.25 39.0 0.98 0.97 3.43 4.45 3.73" 1.28 1.09 109.8 118.0 112.4 1.1 1.03
9.91 5.91 7.44 0.12 0.07 0.29 1.64 0.34 0.36 0.03 20.2 13.9 19.8 0.23 0.06
Choline 31.25 36.5 29.0 1.16 0.93 4.8 8.08 7.35" 1.6 1.5 97.14 127.4 99.8 1.32 1.05
±2.63 ±8.7 ±7.02 ±0.23 ±0.23 ±1.24 ±4.76 ±2.62 ±0.51 ±0.22 ±9.1 ±17.8 ±14.7 ±0.2 ±0.25
Cimetidine 24.5 24.0 30.5° 1.0 1.27 3.18 13.27c 378b 3.85 1.19 70.88 111.2 101.7e 1.58 1.46
± 9.11 ± 6.98 ± 9.43 ± 0.1 ± 0.15 ± 0.33 ± 3.11 ± 0.62 ± 0.78 ± 0.09 ± 17.0 ± 23.93 ± 18.1 ± 0.13 ± 0.19
Amilorjde 23.75 28.0 26.75 1.15 1.13 3.3 8.18" 4.03 2.62 1.25 75.3 1179h 104.8° 1.58 1.4
± 5.12 ± 12.3 ± 4.79 ± 0.35 ± 0.11 ± 0.35 ± 4.89 ± 0.64 ± 1.94 ± 0.34 ± 12.9 ± 30.84 ± 27.1 ± 0.4 ± 0.32
Benzylamiloride 22.75 22.67 29.5 0.96 1.35 2.9 8.63° 3.5 2.87 1.21 66.65 97.83" 90.95" 1.47 1.38
± 8.66 ± 8.96 ± 8.06 ± 0.13 ± 0.29 ± 0.37 ± 2.08 ± 1.17 ± 0.28 ± 0.35 ± 13.0 ± 20.25 ± 14.4 ± 0.19 ± 0.13
2-Methyl-4- 26.5 22.25 33.0 0.85 1.27 3.38 16.4° 4.05 4.27 1.2 88.0" 105.1 118.1 1.19 1.36(heptafluoro- ± 3.79 ± 3.59 ± 2.58 ± 0.19 ± 0.23 ± 0.19 ± 9.87 ± 0.91 ± 2.47 ± 0.23 ± 9.1 ± 26.5 ± 12.9 ± 0.33 ± 0.24
butoxy)-
N-methyl-
pyridinium
Values are means ± SD of four experiments; for concentrations of injected substances see text.
a Inhibitor injected at injection 2
b P < 0.05, P < 0.01, dp < ooo, e P < 0.0001 different from control (injection 1)
for judging the urinary excretion of the third injection of 4-Di-1-
ASP (without inhibitor) after the second injection of 4-Di-1-
ASPcI with inhibitor. In these cases the increase of 4-Di- I -ASP
excretion was always lower (6 ± 9% to 20 ± 18%) than the time
control (27 ± 22%, Table 2). The tissue concentrations of
4-Di-1-ASP show a significant increase as a prolonged effect
(third 4-Di-1-ASP' injection) of the four organic cations cimeti-
dine (46 ± 19%, P < 0.0001), amiloride (40 ± 32%, P < 0.01),
benzylamiloride (38 ± 13%, P < 0.001), and 2-methyl-4-(hep-
tafluorobutoxy)-N-methylpyridinium (36 ± 24%, P < 0.05),
while no increase was seen in time control experiments or with
cho1ine. Under the different maneuvers ['4C]inulin excretion did
not change significantly, so that the fractional excretion rates of
Di-1-ASP showed comparable changes as documented in Table
2 and depicted in Figure 3 A and C. Figure 3 B and D (Table 3)
show a synopsis of the tissue concentration of our test substance
under the influence of the different organic cations tested.
Intracellular distribution pattern of Rho 123 and 4-Di-1-ASP
Figure 4 displays the fluorescence microscopical analysis of
some representative unfixed 4 jim kidney tissue slices, which
showed a similar distribution pattern for both test substances. At
concentrations used in the interaction experiments an intense
diffuse cytoplasmic fluorescence [4-Di-1-ASP and Rho 123
injected at 4.9 msi (0.61 jimol); Fig. 4 A, B] excluding the nucleus
could be ascertained. Injection of lower concentrations [0.98 m'vi
(0.12 jimol) of 4-Di-1-ASP' and 0.098 mtvi (0.0 12 jimol) of Rho
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Fig. 3. Overview of the effects of the four tested
interacting organic cations on fractional excretion
(FE) and tissue fluorescence of 4DI1ASPe
(means of 4 expenmentS SD). A. Fractional
excretion (FE). B. Tissue fluorescence of 4-Di-
1ASP under coinjection with inhibitor. C.
Fractional excretion (FE). 0. Tissue
fluorescence of 4-Di-1-ASP'5 after repeated
injection of 4-Di-1-ASP without inhibitor. The
total volume of the bolus was 0.125 ml
consisting of 4.9 mM 4-Di-1-ASP (0.61 smol),
0.08 ms (0.01 mol) [14Clinulin and interacting
substance at the following concentrations
(amount): choline 74 and 147 mivi (9.25 and
18.4 imol), cimetidine 49 msi (6.1 rmol),
amiioride 24.5 mrvi (3.1 smol), benzylamiloride
24.5 mM (3.1 jsmol), and 2-methyl-4-
(heptafluorobutoxy)-N-methylpyridinium 98
mM (12.3 smol) (*P < 0.05, < 0.01, ***p
< 0.001, < 0.0001).
123] however, whereby the cytoplasmic fluorescence was weaker,
revealed a prominent mitochondrial staining (Fig. 4 C, D).
Discussion
The aims of the present study were: (1) to find a fluorescent
organic cation, the net transport of which, that is, the net secretion
or net reabsorption, by the kidney in situ can be clearly evaluated
and Can be ascribed to identified transport processes of the
proximal tubule; (2) to monitor the intracellular concentration of
the fluorescent organic cation continuously by a noninvasive
method; and (3) to reveal whether other organic cations change
the net transport and tissue concentration of the fluorescent test
substance.
Use of fluorescent dyes
For our purpose we applied a similar technique as in a previous
study with organic anions [3], where fluorescein and sulfofluores-
cein (SF, also known as "visible PAH" [71) were used. These
fluorescent dyes were injected together with labeled inulin into
the jugular vein of rats under osmotic diuresis and the urinary
excretion as well as the fluorescence of the tissue at the surface of
the kidney were measured.
Looking for florescent organic cations, we had to consider that
cationic buffers can be sequestered in the acidic compartments
(endosomes, lysosomes) by nonionic diffusion/ionic trapping [8,
9]. Additionally, cationic fluorescent substances are to a certain
degree bound to cellular constituents and are apparently distrib-
uted in some cellular organdIes, for example mitochondria,
according to the electrical potential difference [10]. Recent inves-
tigations, however, seem to demonstrate that also organic anions
as fluorescence undergo some intracellular compartmentalization
and binding to intracellular organelles [11—13].
From the two fluorescent organic cations which we tested, that
is, Rho 123 and 4-Di-1-ASP, it can be anticipated that only Rho
I.-
5o'
1654 Pietmck and Ullrich: Renal organic cation transport
Fig. 4. Fluorescence microscopy of clyosections of unfixed rat kidney cortex 30 seconds after injection of fluorescent dyes. At concentrations used for
monitoring of the surface fluorescence [A, 4-Di-1-ASP 4.9 mivi (0.61 jxmol); B, Rho 123 4.9 mi (0.61 mol)] a strong diffuse cytoplasmic fluorescence
of proximal tubular cells is seen, the nuclei being not stained. After application of lower concentrations [C, 4-Di-1-ASP 1 mi (0.12 jxmol); D, Rho
123 0.1 mi (0.012 mol)] a rapid staining of mitochondria can be observed (magnification, X 25).
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123 can accumulate in acidic intracellular compartments by
nonionic diffusion/ionic trapping, but not the permanent cationic
substance 4-Di-1-ASP. On the other hand, however, both sub-
strates could be accumulated by the same mechanism, if the acidic
intracellular organdies possess H 7organic cation exchangers. A
recent study with endosomal vesicles indeed showed an ATP
driven, ipH-dependent endosomal uptake of the organic cation
tetraethyIammonium [14].
From the beginning we took these characteristics of the fluo-
rescent organic cations into account and concentrated on whether
the tested substrates gave a good tissue signal which is quickly
reversible. We selected two cationic dyes: rhodamine 123 (Rho
123) with two protonable groups, and chemically related to the
fluoresceins for which our tissue fluorescence detection unit was
adjusted [6], and 4-(4-dimethylaminostyryl)-N-methylpyridinium
(4-Di-1 -ASP), a quaternary ammonium compound which pos-
sesses a permanent positive charge, and in addition one proton-
able group (Table 1). Both substances, because of their fluores-
cence, were originally introduced for vital staining of
mitochondria [10, 15]. Rho 123 is also a substrate for the
P-glycoprotein and has been used to identify multidrug resistant
cells [16, 17], which demonstrates functions other than solely
mitochoridrial staining. 4-Di-1-ASP on the other hand, is a
nontoxic vital fluorescent dye belonging to the class of styrylpyri-
dinium dyes, which are used to stain living nerve terminals and
glomeruli of the olfactory bulb [18, 19]. In a systematic investiga-
tion of the styrylpyridinium dyes, Irion et a! [20] demonstrated
that 4-Di-1-ASP is the least lipophilic dye of the different
derivatives tested, with an n-octanol water partition coefficient
(P01w) of about 0.14. This relatively low hydrophobicity of 4-Di-
1-ASP may be one reason why the selectivity for mitochondria
might be not that high. Also Magrassi, Purves and Lichtman [18]
do not attribute the uniformity and intensity of staining of nerve
terminals with the ethyl derivative solely to mitochondrial stain-
ing, which is in accordance to our observations. The performed
kidney tissue slice experiments (Fig. 4) showed a diffuse intense
cytoplasmic staining at injection concentrations of the two test
substances (4-Di-1-ASP and Rho 123) equivalent to these used
in the inhibitory experiments. Only at much lower injection
concentrations could a rapid mitochondrial staining be demon-
strated. The measured fluorescence at the kidney surface can
therefore be attributed to the presence of the respective fluores-
cent dye in the cytoplasm whereby the binding to other cell
constituents, which is covered by the intense cytoplasmic staining,
could not have contributed essentially to the measured tissue
signal.
The organic cations investigated exhibited different affinities for
the three transport systems (Table 1). Rho 123 has a seventeen-
fold higher affinity for the luminal H47organic cation exchanger
and a sixfold higher affinity for the luminal choline transporter
than for the contraluminal organic cation transporter, while the
affinity of 4-Di-1-ASP for the luminal H/organic cation ex-
changer is threefold and for the luminal choline transporter
sevenfold higher than for the contraluminal organic cation trans-
porter. Thus the higher affinity of both dyes for the luminal
organic cation transporters compared to the contraluminal one
might be responsible for the net reabsorption of both dyes.
Whether the higher reabsorptive rate of Rho 123 compared to
4-Di-1-ASP is due to its higher affinity for the H /organic cation
exchanger remains an open question. Because the urinary excre-
tion of 4-Di-1-ASP was with 16.9 4.2% of injected amount
over 25 minutes much larger than the excretion of Rho 123, of
which only 3.1 0.4% were excreted within the urine, we
preferred the quaternaiy ammonium compound 4-Di-1-ASP as
the test substance for the inhibition studies.
Our finding, that the tissue concentration time curve for the
anionic fluorescent SF and the cationic 4-Di-1-ASP are almost
identical and are quickly reversible, reflects the fact that possible
binding of organic cations to cellular constituents and/or seques-
tration into cellular organelles are in rapid equilibrium with the
cytoplasmic pool. Thereby the concentration in cytoplasm is
determined by the transport processes in the plasma membrane
and possible interactions.
Interference of net reabsorbed dyes with net secreted substrates
The phenomenon of interference of organic cations during
their renal excretion has been subject of several recent investiga-
tions [21—28]. Some studies have shown that interferences exist
even between the transport of organic anions and organic cations
[29—31]. This can occur with so-called hi- or polysubstrates-, that
is, organic cations serving as substrates for the organic cation
transport systems as well as the transport system(s) for organic
anions or other transport systems [32—34]. As already shown for
the renal transport of organic anions [3], we were now able to
demonstrate interactions of different organic cations during their
transport by the kidney in situ.
The organic cations amiloride and cimetidine, which are net
secreted by the kidney [35], in BBMV preparations exhibit the
characteristics of Hi/organic cation exchange with trans-stimula-
tion or cis-inhibition by other organic cations and trans-stimula-
tion by a H gradient [36—38]. Because of its similarity to
amiloride regarding the apparent K1 values to the luminal and
contraluminal transport systems for organic cations it can be
anticipated that this is the case for benzylamiloride as well.
Choline, on the other hand, underlies a bidirectional transport
depending on its plasma concentration [39], As could be demon-
strated recently, a separate transport system for choline is
located on the luminal cell side of the proximal tubule, driven by
the electrical potential difference and not operating in exchange
for H ions [2, 40, 41]. Although the inhibitory substrates all
possess affinities for this transport system (Table 1), several
observations point in the direction of the H!organic cation
exchanger being the more affected by the observed interaction
phenomena. The affinities of each inhibitory substrate for both
luminal transport systems are within the same range. Only cime-
tidine has a much weaker affinity (30-fold) for the luminal
choline transporter. This difference permits making a distinction
regarding the interaction with the luminal transport systems.
Whereas it can be anticipated that both luminal transporters
manage the reabsorption of 4-Di-1-ASP, the pronounced effect
of cimetidine on overall reabsorption of 4-Di-1-ASP (Tables 2
and 3, Fig. 3) speaks in favor of a higher proportion or capacitiy
of the luminal H'1organic cation exchanger for mediating this
effect. As demonstrated (Tables 2 and 3, Fig. 3), choline itself
did not exert a significant effect on the transport of 4-Di-1-ASP.
We can therefore draw the conclusion, that, while injected
simultaneously with test substance, the net secreted interacting
organic cations have trans-stimulated the reabsorption of 4-Di-1-
ASP at the site of the luminal H/organic cation exchanger with
an accumulation of test substance in proximal tubular cells as a
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consequence. The least pronounced effect of 2-methyl-4-(hep-
tafluorobutoxy)-N-methyIpyridinium (Tables 2 and 3, Fig. 3)
with the lowest affinity for the luminal H/organic cation ex-
changer (Table 1) supports this interpretation. A carryover effect
of 4-Di-1-ASP handling was seen after the third control 4-Di-
1-ASP injection in its urinary excretion but not in the tissue
content (Tables 2 and 3, Fig. 3).
In general, the relatively high affinity of the test substance
(4-Di-1-ASP) to the respective transporter limits the use of
inhibitory organic cations, which either must have a higher affinity,
or be applied at a much higher concentration at the transport site
to displace the test substance, which can lead to unwanted
systemic side effects. The aim of reaching a high inhibitor
concentration at the transport site, however, is limited because of
several reasons: first, the high protein binding of the used
substances, second, their low water solubility, and third the small
injection volume which did not permit the application of larger
amounts of inhibitory substrates. Despite these limitations, all
inhibitory organic cations used in this study showed a satisfactory
interaction with the reabsorptive transport of 4-Di-1-ASP with-
out causing severe adverse reactions.
Possible toxic effects by drug interactions
Toxic drug effects, which usually involve proximal tubular cells,
depend on the degree of drug accumulation within these cells.
Since a wide variety of N-containing drugs are transported by the
luminal and contraluminal cation transporters of proximal tubular
cells, cellular accumulation of a similar variety of drugs can cause
adverse effects to the proximal tubular cells. Logically an in-
creased cellular content of drugs within the proximal tubular cells
increase the possibility of adverse drug effects. In this study we
have shown that by drug interactions an increased accumulation
of 4-Di-1-ASP can indeed be evoked. Furthermore, cationic
drugs might be accumulated within the cellular organdies, in
acidic organdies by nonionic diffusion/ionic trapping and addi-
tionally by transporters within these vesicular organdIes [8, 9, 14].
For the future, attention should be paid to such possibilities. In
addition, it should be evaluated how simple drug accumulation
within the acidic endocytotic-lysosomal compartment might
change the physiological function of these organelles, such as the
breakdown of pinocytosed proteins [42], and/or membrane target-
ing/recycling [43].
Conclusions
Altogether, the method used in this study provides a useful tool
to investigate overall transport of organic cations and their
interactions in the kidney in vivo. We have identified two fluores-
cent organic cations, which, besides their excretion within the
urine, can be monitored continuously in superficial tissue of the
kidney. For continuous measurement of the cortical tissue con-
centrations, besides tissue fluorescence techniques, NMR spec-
troscopy has also been applied successfully [44]. By combining the
two parameters, urinary excretion and tissue content, it is possible
to determine the site of interaction at the luminal or contralumi-
nal cell side of the proximal tubule. The performed experiments
show the behavior of a fluorescent test dye which is net rcab-
sorbed and the interference with net secreted organic cations,
among them widely used drugs, resulting in an increased intracel-
lular concentration. From the opposite directions of net transport
one would expect such an effect (trans-stimulation). This can be
considered as an example, that also other organic cationic xeno-
biotics possessing affinity to the proximal organic cation transport-
ers might reach higher intracellular concentration by substrate
(drug) interaction, and finally might exert toxic effects to proximal
tubular cells. For the future, it is desirable to study interaction
phenomena with a eationic fluorescent test substance, net se-
creted by the kidney. In this regard, '9F NMR experiments with
fluor-containing organic cations might be rewarding.
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